Apollo Therapeutics, the commercialisation fund backed by Imperial College London, UCL and Cambridge University, has approved its first four drug discovery projects.
Apollo Therapeutics, a £40m ($50m) commercialisation fund backed by several universities, yesterday announced the first four drug discovery projects that have secured capital.
Launched in January 2016, Apollo is backed by the tech transfer offices of Imperial College London, University College London (UCL) and Cambridge University as well as pharmaceutical firms AstraZeneca, GlaxoSmithKline and Johnson & Johnson.
The fund’s stated mission is to boost medical research translation efforts at the three universities.
The first four projects to secure capital…
